Discovery of 4-[(5-arylidene-4-oxothiazolidin-3-yl)methyl]benzoic acid derivatives active as novel potent allosteric inhibitors of protein tyrosine phosphatase 1B: In silico studies and in vitro evaluation as insulinomimetic and anti-inflammatory agents
Insulin resistance and inflammation are implicated in diabetes mellitus and obesity. Protein tyrosine phosphatase 1B (PTP1B) inhibitors act as insulin-sensitizing agents. New 4-thiazolidinone derivatives were found to be potent PTP1B inhibitors. Several tested compounds exhibited insulinomimetic and/or anti-inflammatory activity. A new lead compound endowed with a promising cellular activity profile was identified.